Javier Briones Meijide

Professor

University of Barcelona

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Javier Briones Meijide is a Professor at the Autonomous University of Barcelona, Spain. His research areas focus on innovative therapies in hematology, particularly CAR-T cell treatments, their optimization, and implications in graft-versus-host disease. He has contributed significantly to the field with recent publications involving clinical optimization strategies and novel therapies for various hematological conditions.

Articles (20)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (12)

Teresa Caballero-Velazquez

Profesor Contratado Doctor Vinculada

Universidad de Sevilla

SPAIN

View details

Miguel Arguello-Tomas

Josep Carreras Leukaemia Research Institute

SPAIN

View details

Nicolas Boissel

Université Paris Cité

FRANCE

View details

Raul Cordoba

SPAIN

View details

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE

View details

Jose F Tomas

Head of Department

Mater Misericordiae University Hospital

SPAIN

View details

José Manuel Soria Fernández

Principal Investigator. Head of Group

Hospital de la Santa Creu i Sant Pau

SPAIN

View details

ANA CAROLINA CABALLERO GONZÁLEZ

Josep Carreras Leukaemia Research Institute

SPAIN

View details

Carmen Álvarez Fernández

Institut de Recerca Sant Pau

SPAIN

View details

albert esquirol

SPAIN

View details

Lucia Lopez Corral

Universidad de Salamanca

SPAIN

View details

Silvana Novelli

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Javier Briones Meijide

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA

Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation

Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.

Optimizing CAR-T treatment: A T<sup>2</sup>EVOLVE guide to raw and starting material selection.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.

Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development.

Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies

Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.

A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.

Marginal zone lymphoma under anti-TNF treatment in Crohn disease.

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.

Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.

Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.

Collaborators (12)

Teresa Caballero-Velazquez

Miguel Arguello-Tomas

Nicolas Boissel

Raul Cordoba

Didier Blaise

Jose F Tomas

José Manuel Soria Fernández

ANA CAROLINA CABALLERO GONZÁLEZ

Carmen Álvarez Fernández

albert esquirol

Lucia Lopez Corral

Silvana Novelli

Make your next move.

Javier Briones Meijide

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

HSP-CAR30 WITH A HIGH PROPORTION OF LESS-DIFFERENTIATED T CELLS PROMOTES DURABLE RESPONSES IN REFRACTORY CD30+ LYMPHOMA

Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation

Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.

Optimizing CAR-T treatment: A T&lt;sup&gt;2&lt;/sup&gt;EVOLVE guide to raw and starting material selection.

Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.

Optimization of a home hospitalization program for hematopoietic stem cell transplantation with ehealth integration and clinical pharmacist involvement.

A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-Cell Stemness Shows Enhanced CAR T-Cell Efficacy in Preclinical and Early Clinical Development.

Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies

Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.

Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.

A randomized phase II study comparing consolidation with a single dose of <sup>90</sup>Y ibritumomab tiuxetan <i>vs.</i> maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.

Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study.

Marginal zone lymphoma under anti-TNF treatment in Crohn disease.

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.

Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.

Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper.

Collaborators (12)

Teresa Caballero-Velazquez

Miguel Arguello-Tomas

Nicolas Boissel

Raul Cordoba

Didier Blaise

Jose F Tomas

José Manuel Soria Fernández

ANA CAROLINA CABALLERO GONZÁLEZ

Carmen Álvarez Fernández

albert esquirol

Lucia Lopez Corral

Silvana Novelli

Make your next move.

Optimizing CAR-T treatment: A T<sup>2</sup>EVOLVE guide to raw and starting material selection.